One of the poorest presentations that I have witnessed by both Miles White and Tom Freyman and the written comments to 4th quarter and total year results were even worse. Danced around many operational issues and had no good reason as to why they were bringing into the US $2 Billion (all of the 2014 Cash Flow from foreign operations) and paying US taxes on these funds. It looks on the surface that the reason is to buy back $2Billion (50million shares or 3%) of stock in order to help make 2014 EPS since Freyman made the statement in the conference that no good prospects for M&A activity on the horizon. If these two want any bonus dollars in 2014 than they need to get their act together. Looks like the analysts came away with the same take as I have.
I have my new Honda CBR parked inside my garage. The only way I was able to buy it was because of an amazing payday I had after trading VISN. I bought VISN at like $2.40 because Hulk Alerts alerted me to buy it. It ran over 400%. I highly recommend everyone to check them out copy and past Hulk Alerts into Google and search
The margins in most of their products are increasing. Overtime as revenues increase, especially in developed countries, net income will make a huge jump. When you know how to run the business good things will eventually happen. Think aging population, Abbot and $$$$.
wow.... lets take this to the woodshed.
Look out below
See ya at the bottom
or whatever you douche bags like to say.
"The previously reported sales disruption in International Nutrition that occurred in August is estimated to have reduced Abbott's total worldwide sales growth by ~1.5 percentage points". Carry over from this summer China recall
ABT was inline on EPS and guidance as they always are.....they haven't hit revs in a few quarters.
This company is solid. Please post some more BS about slow growth (ie 3rd world countries) coupled with the exchange rate slowing revenue. You have to be joking.
Abt missed sales because: 1.) Diabetic sales neg. growth. 2.) Established Pharm Sales in mature markets (ie. Europe) show no growth. 3.) Pediatric sales in China, Vietnam and Saudi Arabia, have negatively been impacted in the 3rd and 4th Quarters. First and Second Qtr 2014 EPS are very low, and it looks like Abbott is bring into US 2014 foreign earnings and paying US taxes to buy back 3% of Abbott outstanding share in order to make 2014 EPS targets.
Abbott Reports Fourth-Quarter and Full-Year 2013 Results
Fourth-Quarter Ongoing EPS of $0.58 (GAAP EPS From Continuing Operations of $0.37)
Achieved Adjusted Operating Margin Improvement in 2013
Launched Multiple New Products in 2013 Across Diverse Business Portfolio
Issues Earnings Outlook for 2014
Date: January 22, 2014
Abbott Park, Illinois (NYSE: ABT) — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2013.
Ongoing diluted EPS was $0.58 in the fourth quarter and $2.01 for the full year, reflecting double-digit growth; reported diluted EPS from continuing operations under GAAP was $0.37 in the fourth quarter and $1.50 for the full year.
Excluding foreign exchange, fourth-quarter worldwide sales increased 3.3 percent on an operational basis. Reported sales increased 0.4 percent, including an unfavorable 2.9 percent effect of foreign exchange. The previously reported sales disruption in International Nutrition that occurred in August is estimated to have reduced Abbott's total worldwide sales growth by approximately 1.5 percentage points.
For the full-year 2013, Abbott expanded its adjusted operating margin by 110 basis points over prior year. This was primarily driven by continuing improvements in Diagnostics and Nutrition. Operating margin under GAAP improved by 320 basis points over prior year.
In 2013, Abbott delivered on a number of new product launches. Highlights include nearly 70 new product launches in Nutrition; XIENCE Xpedition™ drug-eluting stent in the United States and Japan; MitraClip®, Abbott's first-in-class device for the treatment of mitral regurgitation, in the United States; TECNIS® OptiBlue intraocular lens (IOL) in Japan and TECNIS Toric IOL in the United States; ACCELERATOR a3600™, a next-generation automation solution for the core laboratory; and several new diagnostic tests on the ARCHITECT™ platform.
Abbott issues ongoing EPS guidance for the full-year 2014 that reflects double-digit g